Repligen Introduces Next-Generation Chromatography Resins to Advance New Modality Workflows

Rhea-AI Summary

Repligen (NASDAQ:RGEN) announced three new high-performance chromatography resins on Dec. 16, 2025: AVIPure HiPer AAV9, AVIPure HiPer AAV8 affinity resins and HiPer QA anion exchange resin. Built on Tantti DuloCore base bead technology, the convective HiPer resins target next‑generation modalities such as viral vectors and gene therapy.

The company says the resins are engineered to help gene therapy developers accelerate product development, improve molecule stability, and enhance process economics, and that the launch strengthens Repligen's proteins portfolio ahead of broader chromatography resin rollouts planned for 2026.

Key Figures

New chromatography resins 3 products Launch of AVIPure HiPer AAV9, AVIPure HiPer AAV8, and HiPer QA resins

Market Reality Check

$160.58 Last Close

Volume Volume 570,380 vs 20-day avg 680,305 (relative volume 0.84), suggesting no unusual trading ahead of this launch. normal

Technical Shares at $160.58, above 200-day MA of $134.72, trading 12.02% below 52-week high $182.52 and 55.96% above 52-week low $102.965.

Peers on Argus

Peers showed mixed moves: STVN +1.43%, ATR +0.70%, BLCO +0.29% versus declines in TFX -0.46% and MMSI -0.46%, suggesting RGEN’s positive move is more stock-specific than sector-wide.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Nov 26	Conference appearance	Neutral	-0.3%	Participation in Evercore healthcare investor conference with webcast access.
Nov 04	Investor conferences	Neutral	-2.2%	Announcement of attendance at multiple November healthcare investor conferences.
Oct 28	Earnings and guidance	Positive	-5.9%	Q3 2025 revenue growth and raised full-year guidance with solid profitability.
Oct 15	Earnings pre-announcement	Neutral	+0.8%	Scheduling of Q3 2025 report and conference call details.
Aug 22	Conference schedule	Neutral	+4.3%	Planned participation in three major September healthcare conferences.

Pattern Detected

Recent history shows a notable divergence on strong earnings, with shares falling after a positive Q3 2025 report, while conference-related headlines have produced generally modest, mixed reactions.

Recent Company History

Over the last six months, RGEN news has focused on conferences and a key earnings update. The Q3 2025 release on Oct 28 reported higher revenue and raised guidance but saw a -5.92% reaction. Multiple conference participation announcements in August–November 2025 produced relatively small price moves, both positive and negative. Against this backdrop, today’s product launch continues a pattern of operational execution following earlier financial strength and active investor outreach.

Market Pulse Summary

This announcement introduces three new chromatography resins targeting viral vector and gene therapy workflows, expanding RGEN’s bioprocessing toolkit. In recent months, the company reported stronger Q3 2025 results and raised guidance while staying active on the healthcare conference circuit. Investors tracking this news may focus on how adoption of these resins supports the previously reported revenue growth and whether new modality tools deepen RGEN’s position in biotherapeutic manufacturing.

Key Terms

anion exchange resin technical

"AVIPure® HiPer™ AAV8 affinity resins, along with HiPer™ QA anion exchange resin,"

An anion exchange resin is a solid, bead-like material that removes negatively charged particles (anions) from liquids by swapping them for other, less harmful ions—like exchanging seats on a bus so different passengers are in different spots. It matters to investors because these resins are key in water purification, chemical separation and some drug processes, affecting operating costs, regulatory compliance and ongoing service or replacement revenue for companies in those industries.

viral vectors medical

"performance required for new modalities, including viral vectors. These solutions are"

Viral vectors are tools that use viruses to deliver genetic material into cells, often to modify or influence how those cells function. They are important to investors because they are a key technology in gene therapy and biotechnology, industries that are rapidly growing and could lead to new medical treatments. Their effectiveness and safety influence the success and valuation of biotech companies developing these therapies.

gene therapy medical

"help gene therapy developers accelerate product development, improve molecule"

Gene therapy is a medical technique that involves altering or replacing faulty genes in a person's cells to treat or prevent disease. It is considered a promising area of innovation because it has the potential to provide long-term or even permanent solutions to genetic conditions. For investors, advancements in gene therapy can signal opportunities in biotech companies and emerging treatments with significant growth potential.

AI-generated analysis. Not financial advice.

WALTHAM, Mass., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the launch of three new high-performance chromatography resins: AVIPure^® HiPer™ AAV9 and AVIPure® HiPer™ AAV8 affinity resins, along with HiPer™ QA anion exchange resin, expanding the company’s growing proteins portfolio and reinforcing its commitment to innovation in next-generation bioprocessing. Built on the Tantti™ DuloCore™ base bead technology, the new convective HiPer resins deliver the differentiated performance required for new modalities, including viral vectors. These solutions are engineered to help gene therapy developers accelerate product development, improve molecule stability, and enhance process economics, ultimately enabling faster, more reliable paths to market.

As momentum continues across new modalities, Repligen remains focused on providing customers with the cutting-edge tools they need. These new resins extend the company’s leadership in process productivity and strengthen its portfolio ahead of broader chromatography resin launches anticipated in 2026.

“These new resins further expand our growing proteins portfolio with purpose-built, next-generation tools that leverage both our AVIPure^® affinity ligands and HiPer™ bead technologies,” said Umay Saplakoğlu, Vice President, Proteins and Incubator at Repligen. “Gene therapy manufacturers need scalable, high-performance solutions. Our latest AAV8 and AAV9 resins, along with our HiPer QA anion-exchange resin, are designed to deliver significantly faster processing and robust performance across today’s increasingly complex biotherapeutic workflows.”

About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the our company see our website at www.repligen.com, and follow us on LinkedIn.

This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law.

Repligen Contact:
Jacob Johnson
VP, Investor Relations
781-419-0204
investors@repligen.com

FAQ

What did Repligen (RGEN) announce on December 16, 2025?

Repligen announced three new chromatography resins: AVIPure HiPer AAV9, AVIPure HiPer AAV8, and HiPer QA anion exchange, built on Tantti DuloCore bead technology.

How are Repligen's new HiPer resins intended to help gene therapy developers?

They are designed to accelerate product development, improve molecule stability, and enhance process economics for viral vector workflows.

Which viral vector serotypes do Repligen's new affinity resins target?

The new affinity resins specifically target AAV8 and AAV9 viral vector serotypes.

What technology underpins Repligen's new chromatography resins (RGEN)?

The resins use the Tantti DuloCore base bead technology and the company's HiPer convective bead design.

Will Repligen release more chromatography resins after this launch?

Yes, Repligen said these launches strengthen its portfolio ahead of broader chromatography resin rollouts anticipated in 2026.

What product family do the new resins expand within Repligen's offerings?

The new products expand Repligen's proteins portfolio and leverage the AVIPure affinity ligands combined with HiPer bead technologies.